Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Binimetinib and Encorafenib in Metastatic Melanoma with CNS Metastases
NCT05026983Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2021
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of binimetinib, encorafenib in melanoma, sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2021; status: recruiting.
02
Drugs
binimetinibencorafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05026983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05026983.